Ann Jihyae, Sun Wei, Zhou Xing, Jung Aeran, Baek Jisoo, Lee Sunho, Kim Changhoon, Yoon Suyoung, Hong Sunhye, Choi Sun, Turcios Noe A, Herold Brienna K A, Esch Timothy E, Lewin Nancy E, Abramovitz Adelle, Pearce Larry V, Blumberg Peter M, Lee Jeewoo
Laboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea.
Shenyang Pharmaceutical University, Shenyang 110016, China.
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3603-7. doi: 10.1016/j.bmcl.2016.06.010. Epub 2016 Jun 7.
A series of homologous analogues of prototype antagonist 1 and its urea surrogate were investigated as hTRPV1 ligands. Through one-carbon elongation in the respective pharmacophoric regions, N-(3-fluoro-4-methylsulfonamidomethylphenyl)urea was identified as a novel and potent TRPV1 antagonistic template. Its representative compound 27 showed a potency comparable to that of lead compound 1. Docking analysis of compound 27 in our hTRPV1 homology model indicated that its binding mode was similar with that of 1S.
研究了原型拮抗剂1及其脲替代物的一系列同源类似物作为hTRPV1配体。通过在各自药效基团区域进行单碳延长,确定N-(3-氟-4-甲基磺酰胺基甲基苯基)脲为一种新型强效TRPV1拮抗模板。其代表性化合物27显示出与先导化合物1相当的效力。在我们的hTRPV1同源模型中对化合物27进行对接分析表明,其结合模式与1S相似。